使用荧光多重免疫组化对晚期甲状腺癌进行免疫图谱分析
研究采用荧光多重免疫组化(F-MIHC)和多光谱成像(MSI)分析12例远处转移的分化型甲状腺癌(DTC)和16例甲状腺未分化癌(ATC)组织样本的免疫特征。结果显示ATC中PD-L1阳性肿瘤细胞和淋巴细胞浸润显著多于DTC,PD-L1的TPS和CPS在DTC中均为阴性,而在ATC中阳性率分别为81%和94%。作者认为免疫图谱可提供肿瘤微环境信息,有助于筛选免疫治疗候选者。
要点
- ATC每mm²中PD-L1阳性肿瘤细胞(CK+PD-L1+)显著多于DTC(183.5 vs 0.03,p<0.001)。
- ATC中PD-L1或PD-1阳性淋巴细胞显著多于DTC。
- PD-L1的TPS和CPS在全部DTC中为阴性,在ATC中阳性率分别为81%和94%。
核心结论
- 晚期DTC与ATC的免疫图谱存在显著差异,尤其体现在PD-L1表达和淋巴细胞浸润方面。
- 采用F-MIHC和MSI进行免疫图谱分析可提供肿瘤微环境信息,可能有助于筛选免疫治疗候选者。
研究设计与样本
- 收集12例远处转移的DTC患者和16例ATC患者的28份组织样本。
- 采用F-MIHC和MSI检测CD4、CD8、PD-1、PD-L1、叉头盒蛋白3和细胞角蛋白(CK)抗体。
- PD-L1表达采用肿瘤比例评分(TPS)和联合阳性评分(CPS)评估。
主要发现
- ATC样本每mm²中PD-L1阳性肿瘤细胞(CK+PD-L1+)显著多于DTC样本(183.5 vs 0.03,p<0.001)。
- ATC中淋巴细胞浸润较DTC显著增加,且ATC样本中PD-L1阳性或PD-1阳性淋巴细胞显著多于DTC样本。
- PD-L1的TPS在全部DTC样本中为阴性,在81%的ATC样本中为阳性。
- PD-L1的CPS在全部DTC样本中为阴性,在94%的ATC样本中为阳性。
关键数值与推荐
- ATC每mm²中PD-L1阳性肿瘤细胞(CK+PD-L1+)为183.5,DTC为0.03(p<0.001)。
- ATC中PD-L1的TPS阳性率为81%,DTC为阴性。
- ATC中PD-L1的CPS阳性率为94%,DTC为阴性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Advanced thyroid cancers, including differentiated thyroid carcinoma (DTC) with distant metastasis, and anaplastic thyroid carcinoma (ATC), are associated with poor clinical outcomes and limited treatment options. This study aimed to determine the immune profiles of advanced thyroid cancers using fluorescent multiplex immunohistochemistry (F-MIHC) and multispectral imaging (MSI). Methods: Twenty-eight tissue samples were collected from 12 patients who had DTC with distant metastasis and from 16 with ATC. The samples were assessed using F-MIHC and MSI with antibodies against the cell surface molecules, cluster of differentiation (CD)4, CD8, programmed cell death-1 (PD-1), PD ligand 1 (PD-L1), forkhead box protein 3, and cytokeratin (CK). The expression of PD-L1 was evaluated using tumor proportion score (TPS) and combined positive score (CPS). Results: Significantly, more PD-L1-positive tumor cells (CK+PD-L1+) per mm2 were found in ATC samples than in DTC samples (183.5 vs. 0.03, p < 0.001). Lymphocyte infiltration was significantly increased in ATC compared with DTC, with significantly more PD-L1- or PD-1-positive lymphocytes in ATC samples than in DTC samples. The TPS and CPS for PD-L1 expression were negative in all DTC samples but positive in 81% and 94% of ATC samples, respectively. Conclusions: Immune profiling revealed significant differences between advanced DTC and ATC, particularly in terms of PD-L1 expression and lymphocyte infiltration. Therefore, immune profiling using F-MIHC and MSI can provide invaluable information regarding tumor microenvironments, which could help select candidates for immunotherapy.
引用
- Ahn J, Jin M, Song E, et al. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry. Thyroid. 2020. PMID: 32611231. doi:10.1089/thy.2020.0312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。